UNSPSC 51386402: Tepoxalin

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C20H20ClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TZ4OX61974, chemically known as 1h-pyrazole-3-propanamide, 5-(4-chlorophenyl)-n-hydroxy-1-(4-methoxyphenyl)-n-methyl- but generally known as tepoxalin, which bears US NIH Compound Identifier 59757. European Medicines Agency schedules Tepoxalin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10905MIG.

UNSPSC 51386402 Tepoxalin, a Commodity code, shows minimal recent state and local activity directly tied to the product itself. The three most recent solicitations posted under this code involve pharmaceutical procurement, but only one references naloxone and drug deactivation systems; the other two address broader generic pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs unrelated to tepoxalin. State and local buyers under this code span health departments, county community health agencies, and cooperative purchasing alliances serving multiple jurisdictions. Seminole County, Florida issued an IFB (Solicitation IFB60459723LAS, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually for the county's community health initiatives, with quarterly deliveries to the Seminole County Community Health Building. The procurement required electronic bidding through the county's e-Procurement Portal and included standard compliance requirements such as drug-free workplace certification and E-Verify compliance, with an initial two-year contract term and one-year renewal option.

Geographic activity spans Florida, Texas, and Minnesota, with the most recent solicitations originating from Seminole County, Florida (June 2026); the Texas Health and Human Services Commission, which issued an RFI in April 2026 on direct-to-manufacturer prescriptions; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which posted an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities including Oregon. The code shows no dominant issuing body; activity appears episodic rather than concentrated among repeat buyers. No current opportunities targeting tepoxalin specifically are present in the recent posting history, suggesting the code may be misaligned with active state and local demand or that tepoxalin procurement occurs under different UNSPSC classifications.